Alnylam Pharmaceuticals Inc

2.26 (1.22%)


Draw Mode:

Volume 426,725
Bid Price 186.17
Ask Price 190.74
News -
Day High 188.87


52 Week Range


Day Low 184.06
Company Name Stock Ticker Symbol Market Type
Alnylam Pharmaceuticals Inc ALNY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
2.26 1.22% 188.26 00:00:03
Open Price Low Price High Price Close Price Prev Close
186.50 184.06 188.87 188.26 186.00
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,630 426,725 $ 187.15 $ 79,863,705 - 120.43 - 242.97
Last Trade Time Type Quantity Stock Price Currency
16:56:45 38 $ 188.26 USD

Alnylam Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 23.39B 124.22M 124.41M $ 319.29M $ -1.76M -1.40 -13,317.23
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -26.22k 0.10%

more financials information »

Alnylam Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ALNY Message Board. Create One! See More Posts on ALNY Message Board See More Message Board Posts

Historical ALNY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week191.48194.68183.00189.48487,442-3.22-1.68%
1 Month195.13212.47183.00198.77596,357-6.87-3.52%
3 Months193.64212.47179.19197.04766,871-5.38-2.78%
6 Months213.08242.97179.19211.06785,528-24.82-11.65%
1 Year127.19242.97120.43198.84877,29361.0748.01%
3 Years141.06242.97117.58173.09729,90647.2033.46%
5 Years99.33242.9760.27139.59757,08588.9389.53%

Alnylam Pharmaceuticals Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.